AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03081091 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: The needles used for the treatments will be single-use needles of two different gauge sizes. One size or the other will be used depending on the area to be treated and the physical condition of the patient. The needles and gauge sizes used in the study are as follows:~Dong Bang siliconized needle 0.25 mm x 40 mm Dong Bang siliconized needle 0.20 mm x 30 mm~The therapist will assess the patient's condition according to traditional Chinese medicine and will look at the relationship between the patient's most affected areas and the paths of the acupuncture meridians. Subsequently, the combination of Yuan and Luo points to be treated will be determined. This procedure will be followed before every acupuncture session, in such a way that the combination of the points used will depend on the evolution of the symptoms.
Study NCT03081091 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: It will follow the validated technique of sham acupuncture with the Park device, without needle penetration in the patient's body.~The Park device for the performance of sham acupuncture consists of two plastic tubes, one sliding within the other, and inside which the needle created for the device slides. The longest tube is attached to a circular base, which has an adhesive surface that sticks to the skin so that the device and the needle cannot fall. Blunt ended needles will be used for this technique and thus the needle does not get to pass through the skin but produces a cutaneous stimulation similar to conventional acupuncture needles. These needles are supplied with the kit that contains the Park sham acupuncture device and are registered in the European Union as CE 0120.
Study NCT00359294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM00104
Description: Intravenously over 1 hour daily for 5 days, every 3 weeks.
Study NCT01966302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPS-314d-MR
Description: 15-150 mcg po BID,
Study NCT01282333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT01282333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: veliparib
Description: Given orally
Study NCT01282333 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagnostic laboratory biomarker analysis
Description: Correlative studies
Study NCT01282333 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01282333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT00371709 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAXUS Liberté-SR
Description: Paclitaxel-Eluting Coronary Stent System
Study NCT00371709 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: TAXUS™ Express
Description: Paclitaxel-Eluting Coronary Stent System
Study NCT03738761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlessa®
Description: Fixed-dose combination (FDC) of perindopril/amlodipine, tablets. Strengths: 4mg/5 mg, 8mg/5 mg, 8mg/10 mg.
Study NCT03738761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-Amlessa®
Description: Fixed-dose combination (FDC) of perindopril/indapamide/amlodipine, tablets. Strengths: 4mg/1.25 mg/5 mg, 8mg/2.5 mg/5 mg, 8mg/2.5 mg/10 mg.
Study NCT00595101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03187207
Study NCT00595101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%
Study NCT00595101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03187207 Vehicle
Description: One drop in study eye once daily for the first 28 days to all subjects, followed by 28 days in combination with PF-03187207.
Study NCT00595101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost Vehicle
Study NCT00602446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: deferasirox
Description: 20 mg/kg once daily orally for 6 months
Study NCT03124537 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App Experimental condition
Description: This group were given the app to 1) count their steps, 2) add walks to their daily schedules, 3) create maps of their walking routes, and 4) text friends to invite them for a walk. Participants are asked to set a daily step goal and they can see how many steps they've taken each day since using the app. 2) There is an interface where participants can create maps based on walking routes. 3) They will also have the option to use a daily schedule to plan certain times in the day that they can walk. 4) The social feature gives participants the option to message friends, co-workers, or neighbors in one's contact list to invite them for a walk. They were also asked to respond to two questions twice a day about their mood and energy levels.
Study NCT03124537 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App Condition Control
Description: This group received the app with the first component, the ability to count steps and set daily step goals. This group will also be able to track walks to see the time, distance, and steps of each walk, but not see these walks displayed as a map. This group will monitor their daily steps over a one-month period, and will be asked to use the app as much as possible. They were also asked to respond to two questions twice a day about their mood and energy levels.
Study NCT02094248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPO
Description: rhTPO（Recombinant Human Thrombopoietin，TPIAO®, Shenyang Sunshine Pharmaceutical Company Limited \[SUNSHINE\], Shenyang, China）， 15000U/ml, s.c injection
Study NCT02094248 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: Normal saline，1ml/day, s.c injection
Study NCT02455973 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle modification and cardiovascular risk
Description: Group meetings will be performed in the presence of a member of the nursing staff, physiotherapy, nutrition and psychology. The meetings are weekly, lasting 1 hour and 45 minutes. In the first 1 hour and 15 minutes will be addressed health issues related to lifestyle modification (self-care, healthy eating and physical activity) using the fundamentals of motivational interviewing technique. All topics will be focused on the major cardiovascular risk factors considered modifiable.Likewise, it is envisaged to include a time of physical activity (30 minutes) oriented in conjunction with the research team. Run in: There will be a meeting with the parents in order to inform them about the participation of children in the program and guide them about the procedures of the research protocol.
Study NCT02455973 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health Education
Description: The meetings will be weekly with 45 minutes duration on a schedule of lectures about cardiovascular risk
Study NCT01260272 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alternative Snack Comparator
Description: Any prepackaged commercial snack is permitted as an alternative comparator snack, as long as it is 100 kcal/serving, does not contain raisins, does not contain solely fruits, and/or does not contain solely vegetables. Preferred comparator snack examples include: Keebler® Cheez-It® Crackers, Fudge Shoppe ® Grasshopper® Cookies, Fudge Shoppe ® Mini Fudge Stripes ™ Cookies, Nabisco Chips Ahoy! Baked Chocolate Chip Snacks, Honey Maid Cinnamon Roll Thin Crisps, Lorna Doone Baked Shortbread Cookie Crisps, Oreo Baked Chocolate Wafer Snacks, Pepperidge Farm® Goldfish® Baked Snack Crackers
Study NCT01260272 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Raisins
Description: Raisins are dry grape fruits that may be eaten raw, or used in cooking, baking, and brewing. Raisins are mostly composed of carbohydrates (mostly fructose). They are also high in fiber and antioxidants, relatively high in potassium, and low in sodium.
Study NCT00594386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: Rotigotine transdermal patches:~10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours)~Optimal dosing:~During the first year: The maximum Rotigotine dose allowed is 6 mg/24 hours.~After the first year: Allowed dose increase of Rotigotine up to a maximum of 16 mg/24 hours.
Study NCT02702232 — intervention group
Intervention type: OTHER
Intervention: Ultrasonography
Description: Ultrasonography is applied for normal subjects and patients with Parkinson's disease
Study NCT03709121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reproxalap Ophthalmic Solution (0.25%)
Description: Reproxalap Ophthalmic Solution (0.25%) dosed twice.
Study NCT03709121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reproxalap Ophthalmic Solution (0.5%)
Description: Reproxalap Ophthalmic Solution (0.5%) dosed twice.
Study NCT03709121 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Ophthalmic Solution
Description: Vehicle Ophthalmic Solution dosed twice.
Study NCT03756818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mivavotinib
Description: Given PO
Study NCT03756818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT03756818 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic Study
Description: Correlative studies
Study NCT01584700 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Renal Artery Denervation
Description: Radiofrequency ablation of the renal artery sympathetic outflow tract.
Study NCT04573166 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Personalized atrial septostomy with combined use of radiofrequency-ablation and balloon-dilation
Description: After left and right catheterization, CURB procedure will be performed in all patients. The first step is RFA on fossae ovalis; and then graded BAS is carried out after transseptal puncture; finally, RFA is repeated around the fenestration-rim created with BAS. The fenestration-size will be determined based on the level of MLAP, and the immediate size of fenestration will be evaluated with intra-cardiac echocardiography. The patency and size of fenestration will be followed up for 6 months. During the period of follow up, the other evaluations will include the improvement in exercise tolerance, major adverse cardiac and/or cerebrovascular events (MACCE), reduction of PAWP/MLAP at rest, cardiac remodeling, myocardial injury, and so on.
Study NCT02749799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFD-01 (betamethasone dipropionate) Spray, 0.05%
Description: DFD-01 (betamethasone dipropionate) Spray, 0.05% to be applied twice daily on the affected areas (avoiding the face, scalp, groin, axillae and other intertriginous areas) for 28 days.
Study NCT00823758 — intervention group
Intervention type: BEHAVIORAL
Intervention: Focus Groups
Description: 6 to 8 participants per group.
Study NCT00823758 — intervention group
Intervention type: BEHAVIORAL
Intervention: Personal Interviews
Description: Conducted by phone and audiotaped.
Study NCT01146561 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tanezumab
Description: single administration of tanezumab 20 mg sub-cutaneously
Study NCT01146561 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single administration of placebo to match tanezumab, sub-cutaneously
Study NCT03406988 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous fat grafting
Description: Implantation of small amount of autologous adipose tissue at the base of the finger to induce a rapid healing of the distally located DU
Study NCT03406988 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham procedure
Description: Local injection of 0.5ml saline solution after a simulated liposuction procedure.
Study NCT01544764 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment , Feedback, Incentives, and eXchange Program
Description: The NC Immunization Branch uses Adolescent AFIX (Assessment, Feedback, Incentives and eXchange) Program, a quality improvement strategy developed by the CDC to improve the immunization practices and vaccination coverage levels of public and private health care providers. It has four main components: 1) Assessment of a provider's current immunization practices and vaccination levels, 2) Feedback of the assessment results and strategies to improve coverage levels, 3) Incentives to improve coverage levels, and 4) eXchange of information and resources necessary to facilitate improvement.
Study NCT01411098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT03970499 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: brain tumor resection
Description: Intraoperative brain ultrasound elastography and ultrasensitive doppler during surgery
Study NCT02163707 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Psilocybin
Description: Dose 1: 0.3 mg/kg (approximately 20mg/70kg) Dose 2: 0.45 mg/kg (approximately 30 mg/70 kg) Dose 3: 0.6 mg/kg (approximately 40 mg/70 kg)
Study NCT03489200 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EH301
Description: 1-(beta-D-Ribofuranosyl)nicotinamide chloride and 3,5-Dimethoxy-4'-hydroxy-trans-stilbene
Study NCT03489200 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No intervention- placebo
Study NCT01009255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK239512
Description: Histamine H3 Antagonist
Study NCT01009255 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match GSK239512
Study NCT04505306 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Macular Laser
Description: All treatments were performed using SPCW EndPoint 30% and 50% protocols and STMP laser. Patients in the STMP group were treated with the 810-nm diode micropulse scanning laser TxCell™ (IRIDEX Corporation, Mountain View, CA, USA) at 15% duty cycle. Laser was applied in the confluent mode (low intensity/high density) to cover the entire area of the macular edema and leakage as imaged by OCT and/or fundus fluorescein angiography. Patients in the SPCW group were treated with grid pattern laser with 20ms pulse PASCAL laser 532nm (TopCon Medical Laser Systems, Tokyo, Japan) with EndPoint algorithm, which was either 30% or 50% of testing burn with one burn width apart. In both groups, subthreshold power was determined by titrating burn to light (barely visible) burn and switching to either micropulse mode with 15% duty cycle or 30% and 50% EndPoint value.
Study NCT02838576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conjugated Equine Estrogen
Description: Use of conjugated equine estrogen for 12 weeks. Adherence will be monitored during periodical hospital visits in order to receive pills.
Study NCT02838576 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Use of placebo for 12 weeks. Adherence will be monitored during periodical hospital visits in order to receive pills.
Study NCT02174614 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment As Usual (TAU)
Description: Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time.
Study NCT02174614 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual (TAU)
Description: Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time.
Study NCT02174614 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU plus Rapid Abstinence Initiation (RAI)
Description: Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time PLUS the chance to earn money for urine specimens that are negative for cocaine during the first 4 weeks of treatment followed by 8 weeks of CBT4CBT computerized therapy.
Study NCT03905538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FLT-PET/CT
Description: Dose of 0.07 mCi/Kg \[18F\]FLT to max of 5 mCi (± 20%) will be given intravenously.
Study NCT03501654 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TecnisSymfony®
Description: Patients received implantation of unilateral or bilateral TecnisSymfony® IOL after phacoemulsification by a single surgeon (MK Kim).
Study NCT02174614 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU plus RAI plus Cognitive Control Training (CCT)
Description: Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time PLUS the chance to earn money for urine specimens that are negative for cocaine during the first 4 weeks of treatment PLUS sessions of computerized cognitive control training (CCT) 3 times per week for the first 4 weeks followed by 8 weeks of CBT4CBT computerized therapy.
Study NCT03643757 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic epidural analgesia
Description: Before the initiation of the procedure, in the intervention group epidural catheter was inserted by loss of resistance method at the level of T3-T7 with the help of an 18 G Thuohy needle (Pajunk, Geisingen, Germany) while the patient was on sitting position. A test dose of 2 ml, 2% Lidocaine HCL was administered through the catheter. Once, efficacy was confirmed, 10 ml bolus dose of 0.1% Bupivacaine was injected. Analgesia maintenance was provided by infusion of 0.1% Bupivacaine (0.1 ml/kg/hour) both intra- and postoperatively for 24 hours.
Study NCT03643757 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: In addition to multimodal analgesia protocol, epidural bupivacaine was administered in TEA arm and pain relief was achieved by intravenous pethidine infusion in IVA arm.
Study NCT02085473 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tralokinumab 300 mg
Description: Participants will receive 300 milligram (mg) tralokinumab when delivered as a 2 milliliter (mL) subcutaneous injection at different flow rates.
Study NCT02085473 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tralokinumab 300 mg
Description: Participants will receive 300 milligram (mg) tralokinumab when delivered as a 2 milliliter (mL) subcutaneous injection at different flow rates.
Study NCT03981718 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fat grafting
Description: Lipoaspirates will be collected from the own subjects abdominal fat tissue, during the 2nd stage breast reconstruction and will be injected on each affected breast during the insertion of the permanent breast implant in the 2nd stage of breast reconstruction
Study NCT03981718 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fat grafting
Description: Lipoaspirates will be collected from the own subjects abdominal fat tissue, during the 2nd stage breast reconstruction and will be injected on each affected breast during the insertion of the permanent breast implant in the 2nd stage of breast reconstruction
Study NCT04711486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Contraloid acetate
Description: Oral administration of drug substance capsules
Study NCT04711486 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of placebo without any exipients.
Study NCT01473615 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Therapy
Description: A manualized 8-week MBCT group skills program with weekly sessions that each last 2 hours. The MBCT sessions combine elements of cognitive therapy with a mindful approach to thoughts and feelings, including a significant meditation component. The program is specifically tailored to a population that suffers from active depressive symptoms and chronic pain. The program also includes daily homework exercises.
Study NCT02039544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xuebi formula
Study NCT02039544 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT03558282 — intervention group
Intervention type: OTHER
Intervention: Recession Observation
Description: Soft tissue measurements
Study NCT03558282 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Crown Contour Observation
Description: Ultrasound measures of implant crown contour.
Study NCT04919733 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluoroscopy reduction
Description: To decrease, using 3-D mapping systems, the amount of fluoroscopy needed to implant a CIED
Study NCT01498562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib and Nimotuzumab
Description: Combination therapy group: Gefitinib(250mg daily) + Nimotuzumab (200mg weekly)
Study NCT01498562 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib
Description: Mono-therapy group: Gefitinib(250mg daily)
Study NCT01719588 — intervention group
Intervention type: DRUG
Intervention: No intervention
Description: This is an observational study. Prolonged release tapentadol hydrochloride will be administered as per the recommended doses approved in Philippines. The recommended oral starting dose is 50 mg, 100 mg, 150 mg, 200 mg, or 250 mg every 12 hours, with or without food depending on the initial pain intensity and thereafter, the dose will be adjusted to maintain adequate analgesia with acceptable tolerability. The dosing regimen will be individualized according to the severity of pain being treated, the previous treatment experience, and the ability to monitor patients.
Study NCT01242371 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic Supplement
Description: Probiotic Supplement 1 tablet by mouth daily